WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Democrats pounce on Arizona Supreme Court's abortion rulingMax Fried has strong outing against Marlins after uncharacteristically poor start to seasonDemocrats Daniels and Figures stress experience ahead of next week's congressional runoffRetiring Chairman Sean McManus leaves CBS Sports with its critical properties locked up longQB Kellen Mond joining the New Orleans Saints to compete for a backup roleAnonymous accounts use rightCoyotes players informed the team is expected to move to Salt Lake City, AP source saysMax Fried tosses 6 solid innings and Marcell Ozuna homers as Braves beat Marlins 8Rudy Gobert's big night lifts Timberwolves past Hawks and into a firstMax Fried tosses 6 solid innings and Marcell Ozuna homers as Braves beat Marlins 8